Arbutus Biopharma (ABUS) Accumulated Expenses (2014 - 2019)

Arbutus Biopharma (ABUS) has reported Accumulated Expenses for 4 consecutive years, with $137000.0 the latest figure, recorded in Q4 2019.

• Quarterly Accumulated Expenses fell 89.71% year-over-year to $137000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $137000.0 (down 89.71% YoY) and the FY2019 annual result came in at $137000.0, down 89.71% from the prior year.
• Accumulated Expenses retreated to $137000.0 in Q4 2019 per ABUS's latest filing, from $203000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for ABUS reached as high as $1.3 million in Q4 2018 and fell as low as $28000.0 in Q1 2015.
• A 3-year average of $558250.0 and a median of $416500.0 in 2015 frame the typical range for Accumulated Expenses.
• The largest YoY upside for Accumulated Expenses was 89.71% in 2019 against a maximum downside of 89.71% in 2019.
• Year by year, Accumulated Expenses stood at $952000.0 in 2015, then surged by 39.81% to $1.3 million in 2018, then plunged by 89.71% to $137000.0 in 2019.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $137000.0, $203000.0, and $342000.0 for Q4 2019, Q3 2019, and Q2 2019 respectively.